ArticleLeukemia2018
Consequences of mutant TET2 on clonality and subclonal hierarchy.
Open access · greenAbstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 71 citations in OpenAlex.
- Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.Blood cancer journal · 2026Article
- [Molecular and clinical characteristics and prognosis of myelodysplastic neoplasms with biallelic TET2 inactivation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- A new c.681dup RUNX1 variant in familial leukemia.Familial cancer · 2026Article
- Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.Blood advances · 2026Article
- PheCode-guided multi-modal topic modeling of electronic health records improves disease incidence prediction and GWAS discovery from UK Biobank.Briefings in bioinformatics · 2026Article
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion.Cancer medicine · 2025Article
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- Article
- Molecular genetic characterization of myeloid neoplasms with idic(X)(q13) and i(X)(q10).Frontiers in oncology · 2024Article
- The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.Genes, chromosomes & cancer · 2023Article
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Nature communications · 2023Article
- Molecular patterns identify distinct subclasses of myeloid neoplasia.Nature communications · 2023Article
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Research square · 2023Article
- Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.JCI insight · 2023Article
- Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.Journal of experimental & clinical cancer research : CR · 2022Review
- Article
- Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.Experimental hematology & oncology · 2022Article
- Article
- Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.Journal of cancer research and clinical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 3 countries.
Cassandra M HirschDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-2174-6560
Aziz NazhaLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Kassy KneenDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mohamed E AbazeedDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Manja MeggendorferMLL Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Bartlomiej P PrzychodzenDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Niroshan NadarajahMLL Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Vera AdemaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Yasunobu NagataDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Abhinav GoyalDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Hassan AwadaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mohammad Fahad AsadDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Yihong GuanDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mikkael A SekeresLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Ryszard OlinskiDepartment of Clinical Biochemistry, Nicolaus Copernicus University, Bydgoszcz, Poland.
Babal Kant JhaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-7660-5255
Thomas LaFramboiseDepartment of Genetics and Genome Science, Case Western Reserve University, Cleveland, OH, USA.
Tomas RadivoyevitchQuantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9701-1851
Torsten HaferlachMLL Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · USMunich Leukemia Laboratory (Germany) · DECase Western Reserve University · USNicolaus Copernicus University · PL
Funding
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MTherapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MNovel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4MRNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1MInvestigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9MNCI NIH HHS K12 CA076917NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
Abstract
Somatic mutations in TET2 are common in myelodysplastic syndromes (MDS), myeloproliferative, and overlap syndromes. TET2 mutant (TET2
Indexed as
MutationAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesCell DifferentiationClonal EvolutionClone CellsDioxygenasesDisease ProgressionDNA-Binding ProteinsFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteBiomarkers, TumorDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.